
Oranus Mohammadi, MD, outlines how antibody-drug conjugates are transforming breast cancer treatment across subtypes and discusses her approach to sequencing high-cost targeted therapies within payer and clinical practice constraints.
Oranus Mohammadi, MD, outlines how antibody-drug conjugates are transforming breast cancer treatment across subtypes and discusses her approach to sequencing high-cost targeted therapies within payer and clinical practice constraints.
Oranus Mohammadi, MD, discusses the emerging applications of circulating tumor DNA (ctDNA) in breast cancer care and emphasizes the importance of clear communication to help patients navigate uncertain or anxiety-provoking biomarker test results.
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.